Restenosis: Multi-Billion-Dollar Market Tempts Many
This article was originally published in Start Up
Executive Summary
A variety of approaches are being used to combat the problem of restenosis following angioplasty. In addition to separate drug and device efforts, several companies are working on drug-device collaborations to prevent restenosis.
You may also be interested in...
Interventional Innovations Corp.
Surgical Devices; Restenosis. Interventional Innovations is targeting restenosis with a minimally invasive catheter-based x-ray therapy which uses soft, or less energized x-rays. Interventional's system consists of an x-ray cetheter, a delivery sheathand a control unit that allows the physician to increase the depth of penetration, making it possible to tailor the radiation to treat a variety of disease states.
Advanced Coronary Intervention Inc.
Surgical Devices; Restenosis. Advanced Coronary Intervention's guided selective atherectomy process combines real-time ultrasound sensors located on a catheter to guide a physician to a blockage. Radio frequency energy then ablates plaque without damaging arterial walls. Key to the system is the ability to modulate radio frequency energy in such a way that it removes thermocoagulation properties.
CardioGene Therapeutics
Gene Therapy; Cardiovascular; Restenosis. CardioGene has a patented method of promoting gene expression in vascular smooth muscle cells and endothelial cells. The technology also incorporates a double balloon catheter for delivery of the product to theinner wall of the blood vessel. CardioGene also has nine patent applications that include the use of adenovirus vectors to carry genes to vascular smooth muscle cells and means of coating stents with recombinant DNA.